PUBLISHER: Value Market Research | PRODUCT CODE: 1982434
PUBLISHER: Value Market Research | PRODUCT CODE: 1982434
Global Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
The Vaccine Market size is expected to reach USD 229.59 Billion in 2034 from USD 153.30 Billion (2025) growing at a CAGR of 4.59% during 2026-2034.
The global vaccine market has experienced substantial growth due to increasing focus on disease prevention and public health initiatives. Vaccines play a critical role in protecting populations from infectious diseases by stimulating the immune system to recognize and combat harmful pathogens. Governments and healthcare organizations worldwide have expanded immunization programs to improve public health outcomes.
Several factors are driving the growth of the vaccine market. Rising awareness about preventive healthcare and increasing government funding for vaccination programs are major contributors. Advances in biotechnology and vaccine development technologies have also enabled the creation of new and more effective vaccines. Global vaccination campaigns have significantly increased demand for immunization products.
Looking ahead, the vaccine market is expected to continue growing as research institutions develop vaccines for emerging diseases. Technological innovations such as mRNA and advanced delivery systems are improving vaccine effectiveness and production efficiency. With ongoing investments in global healthcare infrastructure, vaccines will remain essential for disease prevention and public health protection.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Vaccine Type
- Inactivated
- Live Attenuated
- Toxoid
- Conjugate
- Others
By Valence
- Monovalent
- Multivalent
By Route of Administration
- Oral
- Injectable
- Others
By Indication
- Influenza
- Hepatitis
- Polio
- Meningococcal Disease
- Pneumococcal Disease
- DTP
- Rotavirus
- MMR
- Human Papilloma Virus
- Others
By Distribution Channel
- Institutional Sales
- Hospital Pharmacies
- Retail Pharmacies
COMPANIES PROFILED
- AstraZeneca, GlaxoSmithKline plc, Sanofi Pasteur SA, Pfizer Inc, Panacea Biotec, Merck Co Inc, Janssen Pharmaceutical Companies, Serum Institute of India Pvt Ltd, Emergent BioSolutions Inc, CSL Limited, Bavarian Nordic, IBSS Biomed SA, Novavax AB, Mitsubishi Tanabe Pharma Corporation
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL VACCINE MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)
- 4.1. Market Analysis, Insights and Forecast Vaccine Type
- 4.2. Inactivated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 4.3. Live Attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 4.4. Toxoid Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 4.5. Conjugate Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
Chapter 5. GLOBAL VACCINE MARKET: BY VALENCE 2022-2034 (USD MN and Million Doses)
- 5.1. Market Analysis, Insights and Forecast Valence
- 5.2. Monovalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 5.3. Multivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
Chapter 6. GLOBAL VACCINE MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)
- 6.1. Market Analysis, Insights and Forecast Route Of Administration
- 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
Chapter 7. GLOBAL VACCINE MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)
- 7.1. Market Analysis, Insights and Forecast Indication
- 7.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.4. Polio Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.5. Meningococcal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.6. Pneumococcal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.7. DTP Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.8. Rotavirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.9. MMR Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.10. Human Papilloma Virus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 7.11. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
Chapter 8. GLOBAL VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)
- 8.1. Market Analysis, Insights and Forecast Distribution Channel
- 8.2. Institutional Sales Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 8.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
- 8.4. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
Chapter 9. GLOBAL VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)
- 9.1. Regional Outlook
- 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.2.1 By Vaccine Type
- 9.2.2 By Valence
- 9.2.3 By Route Of Administration
- 9.2.4 By Indication
- 9.2.5 By Distribution Channel
- 9.2.6 United States
- 9.2.7 Canada
- 9.2.8 Mexico
- 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.3.1 By Vaccine Type
- 9.3.2 By Valence
- 9.3.3 By Route Of Administration
- 9.3.4 By Indication
- 9.3.5 By Distribution Channel
- 9.3.6 United Kingdom
- 9.3.7 France
- 9.3.8 Germany
- 9.3.9 Italy
- 9.3.10 Russia
- 9.3.11 Rest Of Europe
- 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.4.1 By Vaccine Type
- 9.4.2 By Valence
- 9.4.3 By Route Of Administration
- 9.4.4 By Indication
- 9.4.5 By Distribution Channel
- 9.4.6 India
- 9.4.7 Japan
- 9.4.8 South Korea
- 9.4.9 Australia
- 9.4.10 South East Asia
- 9.4.11 Rest Of Asia Pacific
- 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.5.1 By Vaccine Type
- 9.5.2 By Valence
- 9.5.3 By Route Of Administration
- 9.5.4 By Indication
- 9.5.5 By Distribution Channel
- 9.5.6 Brazil
- 9.5.7 Argentina
- 9.5.8 Peru
- 9.5.9 Chile
- 9.5.10 South East Asia
- 9.5.11 Rest of Latin America
- 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
- 9.6.1 By Vaccine Type
- 9.6.2 By Valence
- 9.6.3 By Route Of Administration
- 9.6.4 By Indication
- 9.6.5 By Distribution Channel
- 9.6.6 Saudi Arabia
- 9.6.7 UAE
- 9.6.8 Israel
- 9.6.9 South Africa
- 9.6.10 Rest of the Middle East And Africa
Chapter 10. COMPETITIVE LANDSCAPE
- 10.1. Recent Developments
- 10.2. Company Categorization
- 10.3. Supply Chain & Channel Partners (based on availability)
- 10.4. Market Share & Positioning Analysis (based on availability)
- 10.5. Vendor Landscape (based on availability)
- 10.6. Strategy Mapping
Chapter 11. COMPANY PROFILES OF GLOBAL VACCINE INDUSTRY
- 11.1. Top Companies Market Share Analysis
- 11.2. Company Profiles
- 11.2.1 AstraZeneca
- 11.2.2 GlaxoSmithKline Plc
- 11.2.3 Sanofi Pasteur SA
- 11.2.4 Pfizer Inc
- 11.2.5 Panacea Biotec
- 11.2.6 Merck & Co. Inc
- 11.2.7 Janssen Pharmaceutical Companies
- 11.2.8 Serum Institute Of India Pvt. Ltd
- 11.2.9 Emergent BioSolutions Inc
- 11.2.10 CSL Limited
- 11.2.11 Bavarian Nordic
- 11.2.12 IBSS Biomed S.A
- 11.2.13 Novavax AB
- 11.2.14 Mitsubishi Tanabe Pharma Corporation
